Equitable Holdings, Inc.
EQH
$37.79
+0.45%
Equitable Holdings is a diversified financial services company operating in the insurance industry. It is a major provider of retirement, asset management, and wealth management solutions, leveraging a multi-segment business model to serve individual and institutional clients.
EQH
Equitable Holdings, Inc.
$37.79
Related headlines
Investment Opinion: Should I buy EQH Today?
Based on a synthesis of the data, the objective assessment is a Hold. The stock's deeply discounted valuation (P/S of 1.22) and unanimous analyst 'Buy' ratings create a compelling contrarian case. However, this is heavily counterbalanced by severe technical weakness, negative trailing profitability, and declining revenue. The investment thesis hinges entirely on a successful execution of the earnings recovery implied by the low forward P/E of 3.97, which carries significant uncertainty. Therefore, it is not a clear-cut buy at this juncture.
Sign up to view all
EQH 12-Month Price Forecast
The outlook is bifurcated and highly dependent on the company's ability to translate its strong gross margin and cash flow into consistent bottom-line results. The probability-weighted base case suggests limited upside in the next 12 months without clear evidence of sustained operational improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equitable Holdings, Inc.'s 12-month outlook, with a consensus price target around $49.13 and implied upside of +30.0% versus the current price.
Average Target
$49.13
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$30 - $49
Analyst target range
Wall Street analyst sentiment appears positive based on recent institutional ratings. Firms including Morgan Stanley, Wells Fargo, UBS, JP Morgan, and Barclays have all maintained or initiated 'Overweight' or 'Buy' ratings between January and March 2026. This suggests analysts see value at current levels or anticipate a recovery. However, specific consensus target prices, ratings distribution percentages, and the number of analysts covering the stock are not provided in the data.
Bulls vs Bears: EQH Investment Factors
EQH presents a classic value vs. value trap scenario. The stock is deeply out of favor technically and faces significant profitability headwinds. However, its low valuation, strong analyst support, and recent quarterly earnings recovery suggest the potential for a turnaround if operational execution improves.
Bullish
- Strong Analyst Support: Multiple major banks maintain 'Buy' or 'Overweight' ratings, signaling confidence in a recovery.
- Attractive Valuation Multiples: Low P/S of 1.22 and EV/Sales of 0.53 suggest the stock is trading at a discount.
- Solid Free Cash Flow: TTM free cash flow of $737M provides financial flexibility and supports shareholder returns.
- High Gross Margin: Gross margin of 79.1% indicates strong underlying business profitability.
Bearish
- Severe Technical Downtrend: Stock down ~27% in 6 months, trading near 52-week low of $35.195.
- Volatile and Negative Profitability: Trailing EPS is negative at -$0.097, with a net margin of -11.8%.
- High Operating Expenses: Operating margin is -10.2%, indicating cost control challenges.
- Unusual Capital Structure: Negative Debt-to-Equity ratio of -88.7 suggests potential balance sheet distortions.
EQH Technical Analysis
The stock has been in a pronounced downtrend over the observed period, with the price falling from around $49 in early October 2025 to approximately $35.65 by March 30, 2026. This represents a significant decline, with the 6-month price change at -27.66% and the 3-month change at -25.85%, both substantially underperforming the broader market as indicated by the negative relative strength figures. Short-term performance has been weak, with the stock down 11.36% over the past month. The price action shows a series of lower highs and lower lows, culminating in a sharp drop in late February 2026 from the mid-$40s to below $40, followed by continued weakness into March. The current price of $35.65 is near the bottom of its 52-week range, which spans from $35.195 to $56.61. This positions the stock just above its 52-week low, indicating significant technical weakness and a lack of buying support at recent levels.
Beta
1.10
1.10x market volatility
Max Drawdown
-37.0%
Largest decline past year
52-Week Range
$35-$57
Price range past year
Annual Return
-31.2%
Cumulative gain past year
| Period | EQH Return | S&P 500 |
|---|---|---|
| 1m | -3.8% | -3.6% |
| 3m | -21.2% | -4.0% |
| 6m | -26.1% | -2.0% |
| 1y | -31.2% | +16.2% |
| ytd | -21.2% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EQH Fundamental Analysis
Revenue and profitability have been highly volatile and recently negative. The latest quarterly revenue (Q4 2025) was $3.28 billion, representing a year-over-year decline of 9.5%. More concerning is the net income, which swung to a loss of $1.31 billion in Q3 2025 before recovering to a profit of $215 million in Q4. The trailing twelve-month EPS is negative at -$0.097, and the net margin is -11.83%. Financial health shows mixed signals. The company has a very strong current ratio of 25.5, indicating ample short-term liquidity. However, the debt-to-equity ratio is a highly negative -88.68, which is an unusual and potentially misleading figure often resulting from negative shareholder equity. Free cash flow over the trailing twelve months is positive at $737 million. Operational efficiency metrics are contradictory. Return on Equity (ROE) is reported at a high 18.65%, but this is juxtaposed with a negative Return on Assets (ROA) of -0.196%. The gross margin remains healthy at 79.14%, but the operating margin is negative at -10.23%, pointing to high operating expenses relative to revenue.
Quarterly Revenue
$3.3B
2025-12
Revenue YoY Growth
-0.09%
YoY Comparison
Gross Margin
+0.88%
Latest Quarter
Free Cash Flow
$737000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EQH Overvalued?
Given the negative trailing net income, the Price-to-Earnings (PE) ratio is not a meaningful metric, standing at -10.29. Therefore, we focus on the Price-to-Sales (PS) ratio, which is 1.22. This suggests the market is valuing the company at just over 1 times its sales, which could be considered low for a financial services firm, reflecting the recent profitability challenges. Peer comparison data is not available in the provided inputs. The forward PE ratio is listed at 3.97, which appears very low and may be based on analyst estimates for a significant earnings recovery. The Enterprise Value-to-Sales ratio is 0.53, which also indicates a potentially discounted valuation relative to the company's revenue base.
PE
-10.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~64x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.6x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is the company's volatile and recently negative profitability, as evidenced by a trailing net margin of -11.8% and a significant quarterly loss in Q3 2025. This operational instability is the core driver of the stock's severe underperformance. The negative debt-to-equity ratio, while potentially a reporting artifact, complicates the assessment of financial leverage and health. Furthermore, the stock exhibits high sensitivity to market movements with a beta of 1.1, and its price is near 52-week lows, indicating a lack of investor confidence and potential for further downside if results disappoint. The recent news of share buybacks, while a positive signal, may not be sufficient to offset fundamental concerns if revenue trends do not stabilize.
FAQ
The key risks are operational and financial. The company has shown volatile and recently negative profitability, with a net margin of -11.8% and a significant loss in Q3 2025. Revenue declined 9.5% year-over-year in its latest quarter. Technically, the stock is near its 52-week low after a steep decline, indicating weak momentum. The unusual negative debt-to-equity ratio also complicates the assessment of its financial stability.
The 12-month outlook is highly uncertain. A base case (50% probability) sees a partial recovery to a range of $38-$45, driven by modest earnings improvement. A bull case (30% probability), reliant on a successful turnaround, could see the stock rise to $48-$56. A bear case (20% probability) could see it fall to $32-$36 if operational issues persist. The consensus among analysts is positive, but the stock price has severely diverged from this view.
Based on traditional sales multiples, EQH appears significantly undervalued. Its Price-to-Sales ratio of 1.22 and Enterprise Value-to-Sales ratio of 0.53 are low, suggesting the market is pricing in little growth or significant risk. However, the negative trailing P/E ratio of -10.3 reflects real profitability problems. The forward P/E of 3.97 indicates analysts believe it is deeply undervalued if a sharp earnings recovery materializes, creating a valuation paradox.
EQH is not a clear 'good buy' for most investors at this time. While its valuation appears cheap with a P/S ratio of 1.22 and it has strong analyst support, the stock is in a severe downtrend, down over 27% in six months, and has negative trailing earnings. It is a speculative bet on a turnaround that has yet to be consistently demonstrated, making it a high-risk proposition more suitable for a 'Hold' or watchlist status.
EQH is unsuitable for short-term investment given its high volatility, negative momentum, and dependency on quarterly earnings surprises. It is only suitable for a long-term, patient investor who believes in the analyst thesis of a multi-year turnaround and can withstand significant price fluctuations. The investment case is fundamentally about waiting for operational improvements to be reflected in sustained profits, which is a long-term proposition.